Skip to main content
SpringerLink
Log in

Evidences from Clinical Trials and Use of Antihypertensive Drugs in Children and Adolescents

  • Chapter
  • First Online:
Hypertension in Children and Adolescents

Part of the book series: Updates in Hypertension and Cardiovascular Protection ((UHCP))

  • 556 Accesses

Abstract

In adults, when prescribing antihypertensive therapy, decisions regarding the choice of agent can be based upon evidence from clinical trials in large numbers of subjects, many of these having compared one class of agent with another. Whilst increased emphases on conducting drug trials in children and adolescents over the past 25 years have yielded important advances, and have tested the efficacy and safety of the various classes of antihypertensive agents, there remains a general lack of high quality long-term outcome data to guide choice of drug therapy for pediatricians managing HTN. As of today, certain clinical trials in children and adolescents have established the pharmacokinetics, pharmacodynamics, efficacy lowering BP and safety of many classes of antihypertensive drugs. In the lack of strong evidence to recommend one class of antihypertensive medication over the other, given the substantial efforts that have been made to perform pediatric-specific studies confirming efficacy and safety in children, it seems sensible to commence therapy with those agents which have a license for use on children.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555–76.

    Article  Google Scholar 

  2. Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, et al. European Society of Hypertension. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009;27:1719–42.

    Article  CAS  PubMed  Google Scholar 

  3. Lurbe E, Agabiti-Rosei E, Cruickshank JK, Dominiczak A, Erdine S, Hirth A, Invitti C, Litwin M, Mancia G, Pall D, Rascher W, Redon J, Schaefer F, Seeman T, Sinha M, Stabouli S, Webb NJ, Wühl E, Zanchetti A. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens. 2016;34:1887–920.

    Article  CAS  PubMed  Google Scholar 

  4. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B, Flinn SK, Gidding SS, Goodwin C, Leu MG, Powers ME, Rea C, Samuels J, Simasek M, Thaker VV, Urbina EM; SUBCOMMITTEE ON SCREENING AND MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017;140:e20171904

    PubMed  Google Scholar 

  5. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for pediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Official Journal of the European Union 27/12/2006.

    Google Scholar 

  6. Best Pharmaceuticals for Children Act and Pediatric Research Equity Act. https://www.fda.gov/ScienceResearch/SpecialTopics/PediatricTherapeuticsResearch/ucm509707.htm. Accessed 11 Oct 2018.

  7. Food and Drug Administration Safety and Innovation Act (FDASIA). https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstotheFDCAct/FDASIA/default.htm. Accessed 11 Oct 2018.

  8. Pasquali SK, Sanders SP, Li JS. Oral antihypertensive trial design and analysis under the pediatric exclusivity provision. Am Heart J. 2002;144:608–14.

    Article  PubMed  Google Scholar 

  9. EUROPEAN MEDICINES AGENCY Addendum to the Guideline on Clinical Investigation of Medicinal Products in the Treatment of Hypertension (EMA/238/1995/Rev. 3, 18 November 2010 released in 2015. 26 February 2015 EMA/CHMP/206815/2013 Committee for Medicinal Products for Human Use (CHMP).

    Google Scholar 

  10. Bachmann H. Propranolol versus chlorthalidone—a prospective therapeutic trial in children with chronic hypertension. Helv Paediatr Acta. 1984;39:55–61.

    CAS  PubMed  Google Scholar 

  11. Falkner B, Onesti G, Lowenthal DT, Affrime MB. Use of clonidine monotherapy (versus diuretics) in adolescent hypertension. Chest. 1983;83:425–7.

    Article  CAS  PubMed  Google Scholar 

  12. Sorof JM, Cargo P, Graepel J, Humphrey D, King E, Rolf C, et al. Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo controlled trial. Pediatr Nephrol. 2002;17:345–50.

    Article  PubMed  Google Scholar 

  13. Li JS, Flynn JT, Portman R, Davis I, Ogawa M, Shi H, Pressler ML. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. J Pediatr. 2010;157:282–7.

    Article  CAS  PubMed  Google Scholar 

  14. Batisky DL, Sorof JM, Sugg J, Llewellyn M, Klibaner M, Hainer JW, et al. Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. J Pediatr. 2007;150:134–9.

    Article  CAS  PubMed  Google Scholar 

  15. Flynn JT, Newburger JW, Daniels SR, Sanders SP, Portman RJ, Hogg RJ, et al. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr. 2004;145:353–9.

    Article  CAS  PubMed  Google Scholar 

  16. Webb NJA, Lam C, Loeys T, Shahinfar S, Strehlau J, Wells TG, et al. Randomized, double-blind, controlled study of losartan in children with proteinuria. Clin J Am Soc Nephrol. 2010;5:417–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Gartenmann AC, Fossali E, von Vigier RO, Simonetti GD, Schmidtko J, Edefonti A, et al. Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood. Kidney Int. 2003;64:1450–4.

    Article  CAS  PubMed  Google Scholar 

  18. Trachtman H, Frank R, Mahan JD, Portman R, Restaino I, Matoo TK, et al. Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatr Nephrol. 2003;18:548–53.

    PubMed  Google Scholar 

  19. Benjamin DK Jr, Smith BP, Jadhav P, Gobburu VJ, Murphy DM, Hasselblad V, et al. Pediatric antihypertensive trial failures: analysis of end points and dose range. Hypertension. 2008;51:834–40.

    Article  CAS  PubMed  Google Scholar 

  20. Rogan JW, Lyszkiewicz DA, Blowey D, Khattak S, Arbus GS, Koren G. A randomized prospective crossover trial of amlodipine in pediatric hypertension. Pediatr Nephrol. 2000;14:1083–7.

    Article  CAS  PubMed  Google Scholar 

  21. Cichocka E, Januszewicz P, Wyszynska T. Evaluation of the efficacy and tolerance of three antihypertensive agents used as single-drug therapy, nifedipine, prazosin and acebutolol in severe, idiopathic hypertension in adolescents. Ann Pediatr. 1993;40:119–26.

    CAS  Google Scholar 

  22. Moncica I, Oh PI, ul Qamar I, Scolnik D, Arbus GS, Hebert D, et al. A crossover comparison of extended release felodipine with prolonged action nifedipine in hypertension. Arch Dis Child. 1995;73:154–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Friedman A, Chesney RW, Ball D, Goodfriend T. Effective use of captopril (angiotensin I-converting enzyme inhibitor) in severe childhood hypertension. J Pediatr. 1980;97:664–7.

    Article  CAS  PubMed  Google Scholar 

  24. Morsi MR, Madina EH, Anglo AA, Soliman AT. Evaluation of captopril versus reserpine and frusemide in treating hypertensive children with acute post-streptococcal glomerulonephritis. Acta Paediatr. 1992;81:145–9.

    Article  CAS  PubMed  Google Scholar 

  25. Sinaiko AR, Mirkin BL, Hendrick DA, Green TP, O’Dea RF. Antihypertensive effect and elimination kinetics of captopril in hypertensive children with renal disease. J Pediatr. 1983;103:799–805.

    Article  CAS  PubMed  Google Scholar 

  26. Wells T, Frame V, Soffer B, Shaw W, Zhang Z, Herrera P, et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol. 2002;42:870–80.

    Article  CAS  PubMed  Google Scholar 

  27. Schaefer F, Litwin M, Zachwieja J, Zurowska A, Turi S, Grosso A, et al. Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. J Hypertens. 2011;29:2484–90.

    Article  CAS  PubMed  Google Scholar 

  28. White CT, Macpherson CF, Hurley RM, Matsell DG. Antiproteinuric effects of enalapril and losartan: a pilot study. Pediatr Nephrol. 2003;18:1038–43.

    Article  PubMed  Google Scholar 

  29. Li JS, Berezny K, Kilaru R, Hazan L, Portman R, Hogg R, et al. Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children? Hypertension. 2004;44:289–93.

    Article  CAS  PubMed  Google Scholar 

  30. Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens. 2003;16:795–800.

    Article  CAS  PubMed  Google Scholar 

  31. ESCAPE Trial Group, Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009;361:1639–50.

    Article  Google Scholar 

  32. Trachtman H, Hainer JW, Sugg J, Teng R, Sorof JM, Radcliffe J, for the Candesartan in Children with Hypertension (CINCH) Investigators. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens. 2008;10:743–50.

    Article  CAS  Google Scholar 

  33. Hoy SM, Keating GM. Candesartan cilexetil in children and adolescents aged 1 to <17 years with hypertension: profile report. Paediatr Drugs. 2012;14:61–2.

    Article  PubMed  Google Scholar 

  34. Schaefer F, van de Walle J, Zurowska A, Gimpel C, van Hoeck K, Drozdz D, Montini G, Bagdasorova IV, Sorof J, Sugg J, Teng R, Hainer JW. Candesartan in Children with Hypertension Investigators. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens. 2010;28:1083–90.

    Article  CAS  PubMed  Google Scholar 

  35. Bristol-Meyers Squibb. United States Food and Drug Administration. Summaries of Medical and Clinical Pharmacology Reviews. 2005. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm161894.htm

  36. Shahinfar S, Cano F, Soffer BA, Ahmed T, Santoro EP, Zhang Z, et al. A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens. 2005;18:183–90.

    Article  CAS  PubMed  Google Scholar 

  37. Webb NJA, Wells TG, Shahinfar S, Massaad R, Dankner WM, Lam C, et al. An open-label dose-response study of losartan in hypertensive children. Pediatr Nephrol. 2013;28:1636.

    Article  Google Scholar 

  38. Flynn JT, Meyers KE, Neto JP, de Paula Meneses R, Zurowska A, Bagga A, et al. Efficacy and safety of the angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. Hypertension. 2008;52:222–8.

    Article  CAS  PubMed  Google Scholar 

  39. Ellis D, Moritz ML, Vats A, Janosky JE. Antihypertensive and renoprotective efficacy and safety of losartan. A longterm study in children with renal disorders. Am J Hypertens. 2004;17:928–35.

    CAS  PubMed  Google Scholar 

  40. Wells T, Blumer J, Meyers KE, Neto JP, Meneses R, Litwin M, Vande Walle J, Solar-Yohay S, Shi V, Han G, Valsartan Pediatric Hypertension Study Group. Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension. J Clin Hypertens. 2011;13:357–65.

    Article  CAS  Google Scholar 

  41. Schaefer F, Coppo R, Bagga A, Senguttuvan P, Schlosshauer R, Zhang Y, Kadwa M. Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age. J Hypertens. 2013;31:993–1000.

    Article  CAS  PubMed  Google Scholar 

  42. Meyers KEC, Lieberman K, Solar-Yohay S, Han G, Shi V. The efficacy and safety of valsartan in obese and nonobese pediatric hypertensive patients. J Clin Hypertens. 2011;13:758–66.

    Article  CAS  Google Scholar 

  43. Wells TG, Portman R, Norman P, Haertter S, Davidai G, Wang F. Safety, efficacy, and pharmacokinetics of telmisartan in pediatric patients with hypertension. Clin Pediatr. 2010;49:938–46.

    Article  Google Scholar 

  44. Hazan L, Hernández Rodriguez OA, Bhorat AE, Miyazaki K, Tao B, Heyrman R, Assessment of Efficacy and Safety of Olmesartan in Pediatric Hypertension Study Group. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension. 2010;55:1323–30.

    Article  CAS  PubMed  Google Scholar 

  45. Hazan L, Hernandez Rodriguez OA, Bhorat AE, Miyazaki K, Tao B, Heyrman R. Assessment of Efficacy and Safety of Olmesartan in Pediatric Hypertension (AESOP) Study Group. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension. 2010;55:1323–30.

    Article  CAS  PubMed  Google Scholar 

  46. Sinaiko AR, Mirkin BL. Management of severe childhood hypertension with minoxidil: a controlled clinical study. J Pediatr. 1977;91:138–42.

    Article  CAS  PubMed  Google Scholar 

  47. Chaturvedi S, Lipszyc DH, Licht C, Craig JC, Parekh R. Pharmacological interventions for hypertension in children. Cochrane Database Syst Rev. 2014;2:CD008117.

    Google Scholar 

  48. Burrello J, Erhardt EM, Saint-Hilary G, Veglio F, Rabbia F, Mulatero P, Monticone S, D’Ascenzo F. Pharmacological Treatment of Arterial Hypertension in Children and Adolescents: A Network Meta-Analysis. Hypertension. 2018;72:306–13.

    Article  CAS  PubMed  Google Scholar 

  49. https://www.clinicaltrialsregister.eu/ctr-search/search. Accessed 1 Oct 2018.

  50. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, Authors/Task Force Members. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953–2041.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Hypertension Clinic, Hospital Clinico de Valencia, University of Valencia, Valencia, Spain

    Josep Redon

  2. INCLIVA Research Institute, Valencia, Spain

    Josep Redon

  3. CIBER Fisiopatología Obesidad y Nutrición (CB06/03), Instituto de Salud Carlos III, Madrid, Spain

    Josep Redon

  4. Pediatric Department, Consorcio Hospital General Universitario de Valencia, Valencia, Spain

    Pau Redon

  5. CIBER Fisiopatología Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, Spain

    Pau Redon

Authors
  1. Josep Redon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pau Redon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Josep Redon .

Editor information

Editors and Affiliations

  1. Head of Pediatrics Department, Hospital General Universitario Valencia, Valencia, Spain

    Empar Lurbe

  2. Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany

    Elke Wühl

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Redon, J., Redon, P. (2019). Evidences from Clinical Trials and Use of Antihypertensive Drugs in Children and Adolescents. In: Lurbe, E., Wühl, E. (eds) Hypertension in Children and Adolescents. Updates in Hypertension and Cardiovascular Protection. Springer, Cham. https://doi.org/10.1007/978-3-030-18167-3_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-18167-3_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-18166-6

  • Online ISBN: 978-3-030-18167-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation